Meldonium Olpha

Meldonium, the active ingredient in Meldonium Olpha, is a cardioprotective agent presented as an oral dosage form for oral use. It improves myocardial energy metabolism and reduces ischemic injury, and is indicated for the management of ischemic heart disease, angina pectoris, chronic heart failure and peripheral vascular disease in adult patients.

GNH USA supplies Meldonium Olpha as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, ensuring quality compliance with EU standards.

Meldonium is used as an anti‑ischemic agent to improve cardiac energy utilization in several cardiovascular conditions.

- Ischemic heart disease: improves myocardial efficiency and reduces frequency of angina episodes. - Angina pectoris: alleviates chest pain by shifting myocardial metabolism toward glucose utilization. - Chronic heart failure: supports cardiac output by enhancing energy production under low‑oxygen conditions.

Meldonium may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Headache - Dizziness - Insomnia

Serious or Rare Side Effects: - Hypotension - Cardiac arrhythmia - Elevated liver enzymes - Severe allergic skin reaction (e.g., rash, urticaria)

When prescribing Meldonium, clinicians should consider the following precautions to ensure safe use.

- Renal impairment: monitor renal function as the drug is primarily excreted unchanged in urine. - Hepatic dysfunction: use with caution and assess liver enzymes periodically. - Elderly patients: initiate therapy at a lower dose and observe tolerance. - Concomitant anti‑arrhythmic therapy: evaluate for additive effects on cardiac rhythm. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Meldonium can interact with other medicines; interactions are classified by their clinical significance.

Major Interactions (Avoid): - Beta‑blockers: may potentiate bradycardia and excessive reduction in heart rate. - Calcium channel blockers: risk of additive cardiac depression and hypotension. - Strong CYP450 inhibitors: may increase Meldonium plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure for synergistic effects. - Anticoagulants: observe for increased bleeding tendency. - Statins: watch for potential muscle toxicity when combined.